<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="and foci of YFV RNA replication can be revealed by" exact="immunofluorescence" post="staining and membrane flotation assays. Using an antibody against"/>
 <result pre="outbreak. â€¢Antibodies of various YFV proteins facilitate study of YFV" exact="infection" post="and pathogenesis. â€¢Development of antibody-based assays provide tools for"/>
 <result pre="infection and pathogenesis. â€¢Development of antibody-based assays provide tools for" exact="screening" post="of YFV antivirals. â€¢The set of antibodies and assays"/>
 <result pre="antivirals. Keywords Yellow fever virus Antibody Antiviral assay High throughput" exact="screening" post="Antiviral 1 Introduction Yellow fever is a mosquito-borne disease"/>
 <result pre="is a mosquito-borne disease caused by yellow fever virus (YFV)" exact="infection" post="and frequently associated with a severe form of hemorrhagic"/>
 <result pre="rate of up to 60% (Monath and Vasconcelos, 2015). YFV" exact="infection" post="can be prevented by the attenuated 17D vaccine and"/>
 <result pre="and vaccination campaigns has significantly reduced the incidence of YFV" exact="infection" post="in the human population. However, the virus remains in"/>
 <result pre="This outnumbers the estimated death toll of global dengue virus" exact="infection" post="(http://www.who.int/mediacentre/factsheets/fs100/en/). The World Health Organization and its partners responded"/>
 <result pre="to develop safe and highly efficacious antiviral strategies against YFV" exact="infection" post="that can be used not only for treating infected"/>
 <result pre="only for treating infected patients, but also for the prophylactic" exact="treatment" post="of individuals potentially exposed to YFV, since sufficient post-vaccination"/>
 <result pre="individuals). Presently, there is no antiviral drug available for the" exact="treatment" post="and/or prevention of yellow fever (Beasley et al., 2015;"/>
 <result pre="24-well plates and infected with YFV at 1 multiplicity of" exact="infection" post="(MOI) for 24Â h. The cells were either fixed"/>
 <result pre="(GTX134030) was used at 1:500 dilution. J2 antibody used for" exact="detection" post="of double-stranded RNA was diluted at 1:1000. Alexa Fluor"/>
 <result pre="to calculate average percent of NS4B positive cells or total" exact="immunofluorescence" post="intensity. 2.11 Statistical analysis Zâ€² factor (Zâ€²) was calculated"/>
 <result pre="where t is value of each test well. Other high-throughput" exact="screening" post="parameters were determined as described (Liu et al., 2017)."/>
 <result pre="the corresponding viral proteins in YFV-infected cells using an indirect" exact="immunofluorescence" post="assay. Six of the ten antibodies, including the antibodies"/>
 <result pre="failed to detect YFV proteins in YFV-infected cells under the" exact="immunofluorescence" post="assay conditions described above. Both of the antibodies were"/>
 <result pre="Fig. 2 Detection of YFV proteins in YFV-infected cells by" exact="immunofluorescence" post="assay. Huh-7Â cells were seeded on 24-well plates and"/>
 <result pre="only a fraction of the cultured cells was infected. An" exact="immunofluorescence" post="assay was performed to detect the subcellular localization of"/>
 <result pre="However, the cytoplasmic DENV NS5 protein is barely detectable by" exact="immunofluorescence" post="staining due to its relatively low levels and poor"/>
 <result pre="localization of YFV proteins and dsRNAs in YFV-infected cells by" exact="immunofluorescence" post="assay. Huh-7Â cells were seeded on round coverslips in"/>
 <result pre="upon the suppression of cellular RNA synthesis by actinomycin D" exact="treatment" post="that specifically inhibits DNA-dependent RNA transcription, the RNA-dependent viral"/>
 <result pre="RNA synthesis in infected cells. In conjunction with the immunofluorescent" exact="detection" post="of viral nonstructural proteins, the click chemical visualization of"/>
 <result pre="with the ER membrane marker calnexin in fraction 2. Furthermore," exact="treatment" post="of the ER membranes (fraction 2 from the experiment"/>
 <result pre="and distributed into fractions with soluble proteins (Fig. 5B), However," exact="treatment" post="of the ER membranes with the mild detergent digitonin"/>
 <result pre="containing ER membranes (fraction 2) was collected and subjected to" exact="treatment" post="with indicated detergents, followed by a second round of"/>
 <result pre="in a replication-dependent manner was also employed for antiviral compound" exact="screening" post="(Patkar et al., 2009). Recently, we developed an interferon"/>
 <result pre="(designated as BDAA) (Guo et al., 2016) dose-dependently inhibited YFV" exact="infection" post="as judged by a significantly reduced fluorescence intensity revealed"/>
 <result pre="Imaging (HCI) assay was also established with YFV NS4B antibody-based" exact="immunofluorescence" post="staining in combination with image analysis and processing using"/>
 <result pre="CX7 High-Content Screening Platform (ThermoFisher). The assay allows for the" exact="detection" post="of host cells with DAPI staining as well as"/>
 <result pre="images and the dose-dependent reduction of NS4B-positive signals following the" exact="treatment" post="with antiviral compound BDAA. Fig. 6C shows a quantitative"/>
 <result pre="384-well plate) using percentage cells with NS4B signal or total" exact="immunofluorescence" post="intensity. The two types of analyses reveal a similar"/>
 <result pre="staining are shown as a function of doses of BDAA" exact="treatment" post="(B). Quantitation of percentage of cells with positive NS4B"/>
 <result pre="assay was also evaluated for its performance as a high-throughput" exact="screening" post="platform. As shown in Fig. 7 A, while mock-treated"/>
 <result pre="the YFV NS4B antibody can serve as a high-throughput antiviral" exact="screening" post="assay with a cutoff z-score value of âˆ’3. As"/>
 <result pre="maximize therapeutic benefit. Fig. 7 Development of high-content imaging-based high-throughput" exact="screening" post="assay for YFV. (A) Huh-7Â cells were seeded on"/>
 <result pre="8 checkerboard matrix fashion for additional 48Â h followed by" exact="detection" post="of YFV NS4B and quantification of fluorescent signals (nÂ"/>
 <result pre="=Â 5). The EC50 values were obtained by plotting mono" exact="treatment" post="dose response curves. Synergistic plot was generated using MacSynergy"/>
 <result pre="factors. The antibody-based assays are also proved invaluable in the" exact="screening" post="for, and elucidation of the mode of action of,"/>
 <result pre="monoclonal antibodies to yellow fever virus and application in antigen" exact="detection" post="and IgM capture enzyme-linked immunosorbent assayClin. Vaccine Immunol.23201668969727307452 BeasleyD.W.McAuleyA.J.BenteD.A.Yellow"/>
 <result pre="Exp. Med.20520083119313119047440 GuoF.WuS.JulanderJ.MaJ.ZhangX.KulpJ.CuconatiA.BlockT.M.DuY.GuoJ.T.ChangJ.A novel benzodiazepine compound inhibits yellow fever virus" exact="infection" post="by specifically targeting NS4B proteinJ. Virol.90201615 GuoF.ZhaoX.GillT.ZhouY.CampagnaM.WangL.LiuF.ZhangP.DiPaoloL.DuY.XuX.JiangD.WeiL.CuconatiA.BlockT.M.GuoJ.T.ChangJ.An interferon-beta promoter"/>
 <result pre="drug discovery: progress and prospectsAntivir. Res.100201350051924076358 LiuB.TangL.ZhangX.MaJ.SehgalM.ChengJ.ZhangX.ZhouY.DuY.KulpJ.GuoJ.T.ChangJ.A cell-based high throughput" exact="screening" post="assay for the discovery of cGAS-STING pathway agonistsAntivir. Res.1472017374628982551"/>
 <result pre="SantosC.N.Development of a quantitative NS1-capture enzyme-linked immunosorbent assay for early" exact="detection" post="of yellow fever virus infectionSci. Rep.720171622929176643 RiceC.M.LenchesE.M.EddyS.R.ShinS.J.SheetsR.L.StraussJ.H.Nucleotide sequence of"/>
 <result pre="Virol.711997847584819343204 StockN.K.EscadafalC.AchaziK.CisseM.NiedrigM.Development and characterization of polyclonal peptide antibodies for the" exact="detection" post="of Yellow fever virus proteinsJ Virol Methods222201511011626086983 WelschS.MillerS.Romero-BreyI.MerzA.BleckC.K.WaltherP.FullerS.D.AntonyC.Krijnse-LockerJ.BartenschlagerR.Composition and"/>
 <result pre="and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the" exact="treatment" post="of dengue virus infectionJ. Med. Chem.5520126061607522712544 ZhangJ.H.ChungT.D.OldenburgK.R.A simple statistical"/>
 <result pre="parameter for use in evaluation and validation of high throughput" exact="screening" post="assaysJ. Biomol. Screen41999677310838414 ZhengA.YuanF.KleinfelterL.M.KielianM.A toggle switch controls the low"/>
</results>
